Ibogaine for Traumatic Brain Injury (TBI): Stanford Study Results
Stanford’s January 2024 study reported improvements in day-to-day functioning, cognition, PTSD, and depression in veterans with treatment-resistant TBI — a population that had failed every conventional treatment.
What did the Stanford study find for ibogaine and TBI?
In 30 special-operations veterans with mostly mild TBI, disability scores fell from 30.2 at baseline to 5.1 one month after a single magnesium–ibogaine treatment, with gains in processing speed and executive function and no decline on any measure. Open-label, no control group.
How much did disability scores fall after treatment?
WHODAS 2.0 total score, 30 male special-operations veterans with traumatic brain injury, single magnesium-ibogaine treatment. Cherian et al., Nature Medicine, 2024. Open-label, no control group.
♥ IBOGAINE FOR TBI
What did the Stanford study find for ibogaine and TBI?
Disability scores fell to non-clinical levels at one month
Stanford’s January 2024 study reported improvements in day-to-day functioning, cognition, PTSD, and depression in veterans with treatment-resistant TBI — a population that had failed every conventional treatment.
baseline to one month
reduction
(all Spec Ops)
events
The Stanford Study: A Breakthrough for TBI Treatment
Published in Nature Medicine (published online 5 January 2024), the study — run by Stanford University School of Medicine with Ambio Life Sciences, Palo Alto University and the VA Palo Alto Health Care System — enrolled 30 US Special Operations veterans — Navy SEALs, Army Rangers, Green Berets — who had sustained multiple traumatic brain injuries and developed treatment-resistant PTSD. Every participant had failed conventional treatments: SSRIs, therapy, VA programs, and other interventions.
Treatment took place at a licensed ibogaine clinic in Mexico under physician supervision with cardiac monitoring. Results were assessed at 1-month follow-up using validated neuropsychological and psychiatric scales.
“MISTIC resulted in significant improvements in functioning both immediately and 1 month after treatment and in PTSD, depression and anxiety at 1 month after treatment. There were no unexpected or serious adverse events. Controlled clinical trials to assess safety and efficacy are needed to validate these initial open-label findings.”
Cherian KN, Keynan JN, et al., Nature Medicine 2024;30(2):373–381 — observational, open-label, no control group
Why Ibogaine May Help TBI Where Other Treatments Fail
Neuroinflammation Reduction via Sigma-1 Receptors
TBI causes chronic neuroinflammation that persists for years. Ibogaine acts as a sigma-1 receptor agonist, which has known anti-inflammatory effects on the central nervous system — reducing the ongoing inflammatory cascade that perpetuates TBI symptoms.
GDNF and BDNF — Neural Repair Factors
Ibogaine triggers significant upregulation of GDNF (glial cell line-derived neurotrophic factor) and BDNF (brain-derived neurotrophic factor). These are the brain’s primary repair molecules — they promote neurogenesis, synaptic plasticity, and the repair of damaged neural circuits.
Neuroplasticity Window
Ibogaine opens a prolonged period of enhanced neuroplasticity — the brain’s ability to reorganize and form new connections. For TBI patients, this window may allow the brain to recruit compensatory pathways and begin functional recovery that was previously impossible.
Trauma Processing — The Co-Occurring PTSD Problem
In veterans especially, TBI and PTSD are deeply intertwined — the trauma that caused the injury also leaves psychological wounds. Ibogaine addresses both simultaneously: the neurological damage through its pharmacology, and the psychological trauma through the psychedelic experience itself.
Who Is a Candidate for Ibogaine TBI Treatment?
The Stanford study specifically enrolled patients with treatment-resistant conditions — meaning ibogaine may be most valuable when conventional approaches have not worked. Ideal candidates include:
✓
Veterans with combat-related TBI who have not responded to VA treatment programs
✓
Athletes with concussion history and post-concussion syndrome (CTE risk)
✓
First responders (police, firefighters, EMTs) with occupational TBI
✓
Patients with TBI who also have concurrent PTSD, depression, or substance use disorder
✓
Anyone with cognitive symptoms (memory, focus, executive function) following brain injury
Veteran Resources
Veterans facing financial barriers to ibogaine treatment may be eligible for grants and scholarships from:
Heroic Hearts Project (heroicheartsproject.org) — provides grants for veterans seeking psychedelic-assisted therapy
VETS (Veterans Exploring Treatment Solutions) — veteran-focused psychedelic therapy organization
April 2026 Executive Order (Accelerating Medical Treatments for Serious Mental Illness, 18 April 2026) — directed the FDA to prioritise psychedelic drug reviews and, with the DEA, to open a Right to Try pathway that includes ibogaine compounds
What was the study’s primary outcome, and why does it matter?
The primary outcome was the change in WHODAS 2.0 disability scores measured immediately after treatment. The one-month PTSD, depression and anxiety results that circulate most widely were secondary outcomes. Both were reported; only the first was the question the protocol was built to answer.
That is not a technicality. A secondary outcome in an open-label study of 30 people is a signal worth following, not a finding worth betting on, and the authors were explicit that controlled trials are needed to validate what they saw. The study is registered publicly on ClinicalTrials.gov as NCT04313712, so the protocol can be read rather than taken second-hand.
Two further details are almost always dropped in summaries of this research. The cohort was 30 male Special Operations veterans with predominantly mild TBI — not moderate or severe brain injury, not women, not civilians. And magnesium was co-administered as part of the protocol specifically because ibogaine has been associated with fatal cardiac arrhythmia. A programme quoting MISTIC’s results while running a different protocol is not offering what produced them.
What has been published since?
Work on mechanism. In June 2026, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging carried an article on changes in brain metabolism and connectivity after ibogaine administration in veterans with traumatic brain injury — the question MISTIC could measure the effects of but not explain.
The piece, by Gregory A. Fonzo of the McGill Center for Psychedelic Research and Therapy at UT Austin’s Dell Medical School, appears at Biol Psychiatry Cogn Neurosci Neuroimaging 2026;11(6):615–617. Imaging work of this kind is how an observational signal either becomes a mechanism or fails to. It is the part of this story to watch over the next two years, and it is why we tell families that the honest answer to “does it work for TBI?” in 2026 is still “the early data is striking and the trials that would settle it have not been run.”
If you are working through this for a specific person, the practical pages are more useful than the literature: what treatment involves for veterans, the screening a serious programme runs, what happens in the weeks afterwards, and where the regulatory pathway stands.
Ready to Explore Ibogaine for TBI?
We specialize in connecting veterans and TBI patients with clinics that have experience with neurological and trauma applications. Consultation — no pressure.
Related on this site: ibogaine for veterans · veterans with TBI · Parkinson's and neurological conditions · ibogaine safety guide · what treatment costs
What do people ask about Ibogaine for Traumatic Brain Injury (TBI)?
Was the Stanford TBI study controlled?
No. It was an open-label study of 30 male Special Operations veterans with mostly mild TBI and no control group. The authors said controlled trials are needed to confirm the findings.
Why was magnesium given with ibogaine in the study?
Magnesium was co-administered as part of the protocol because ibogaine has been associated with fatal cardiac arrhythmia. It was one of the ways the study managed heart risk.
Were there serious side effects in the Stanford study?
The authors reported no unexpected or serious adverse events among the 30 participants, who were treated at a licensed clinic in Mexico under physician supervision with cardiac monitoring.
Where can I read the study protocol?
It is registered on ClinicalTrials.gov as NCT04313712, and the results were published in Nature Medicine in January 2024 (Cherian et al.).
Sources and further reading
- Nature Medicine (2024): magnesium–ibogaine therapy in veterans with traumatic brain injury — open-label, n=30, no control group
- SAMHSA National Helpline (1-800-662-HELP) — free, confidential, 24/7
Speak with an advisor.
A confidential conversation about your situation and the options actually worth considering — from people who visit every provider they recommend.